Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers [0.03%]
GSK3326595（一种PRMT5抑制剂）单药或联合派姆单抗治疗晚期癌症患者的Ib期和剂量扩展研究
M M Gounder,P Martin-Romano,A Italiano et al.
M M Gounder et al.
Background: Protein arginine methyltransferase 5 (PRMT5) inhibition often leads to a decrease in cell growth and survival in cancer cell lines. GSK3326595 is a first-generation PRMT5 inhibitor. ...
Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline [0.03%]
转移性乳腺癌EMSO指南更新系统治疗推荐意见
D Trapani,D Martins-Branco,G Curigliano et al.
D Trapani et al.
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients [0.03%]
A-BRAVE试验：在高危三阴性早期乳腺癌患者中使用抗PD-L1药物阿维鲁单抗的III期随机临床试验
P F Conte,M V Dieci,G Bisagni et al.
P F Conte et al.
Background: The A-BRAVE trial evaluated the efficacy of avelumab, an anti PD-L1 antibody, as adjuvant treatment for patients with early triple-negative breast cancer (TNBC) at high-risk. ...
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma [0.03%]
仑伐替尼联合派姆单抗与安慰剂联合派姆单抗一线治疗不可切除或转移性黑色素瘤的3期LEAP-003随机双盲研究
A Arance,M-A Berciano-Guerrero,J Guo et al.
A Arance et al.
Background: Lenvatinib plus pembrolizumab demonstrated antitumor activity in advanced melanoma after prior anti-PD-(L)1 therapy in LEAP-004. Here, we report results from LEAP-003 (NCT03820986) which evaluated first-line l...
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† [0.03%]
早期和局部晚期非小细胞肺癌：诊断、治疗和随访指南
A Zer,M-J Ahn,F Barlesi et al.
A Zer et al.
Surgical diagnosis should be limited to cases with small high-risk nodules, including those with negative positron emission tomography (PET)-CT findings and/or inability to obtain tissue by less invasive procedures.10 Radiological criteria ...
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma [0.03%]
循环肾损伤分子-1(KIM-1)与肾细胞癌辅助免疫治疗预后的相关性研究
B I Rini,L Albiges,X Tang et al.
B I Rini et al.
Background: Adjuvant immunotherapy is currently the standard of care for patients with resected renal cell carcinoma (RCC) at increased risk of recurrence, but there are no biomarkers available to guide treatment. Kidney ...
Mechanism-Enhanced Population Science: Strengthening Population Studies Through Mechanistic Insights [0.03%]
机制增强的人口科学：通过机制洞察力加强人口研究
Tej Pandya,Yin Cao,Karl Smith-Byrne et al.
Tej Pandya et al.
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial [0.03%]
转移性激素敏感型前列腺癌患者PSA最低值的十年生存率：ECOG-ACRIN 3805（CHAARTED）试验的长期生存分析
A Tripathi,Y Chen,D F Jarrard et al.
A Tripathi et al.
Background: The CHAARTED trial investigated the long-term survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without docetaxel (D). This ...
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO [0.03%]
一线治疗转移性结直肠癌疾病进展风险的分析以指导疾病的重新评估——AIO和GONO的11项试验分析结果
M M Germani,V Heinemann,D Rossini et al.
M M Germani et al.
Background: We evaluated the distribution and risk of disease progression (PD) in first-line therapy of unresected metastatic colorectal cancer (mCRC) patients receiving chemotherapy + biologics. The aim of the analysis i...
Incidence Trends and Long-Term Survival in Early-Onset Colorectal Cancer: A Nationwide Swedish Study [0.03%]
瑞典全国范围内早期结直肠癌的发病趋势和长期生存研究
Shabane Barot,Annelie Liljegren,Caroline Nordenvall et al.
Shabane Barot et al.
Background: Early-onset colorectal cancer (EOCRC, diagnosis before age 50) is increasing globally. However, survival comparisons with late-onset colorectal cancer (CRC) are inconsistent, and long-term excess mortality rem...